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ARTICLE OPEN
A recombinant conjugated pneumococcal vaccine that protects
against murine infections with a similar efﬁcacy to Prevnar-13
Mark Reglinski1,2, Giuseppe Ercoli 1, Charlie Plumptre1,2, Emily Kay2, Fernanda C. Petersen3, James C. Paton4, Brendan W. Wren2 and
Jeremy S. Brown1
The pneumococcal conjugate vaccine (PCV) strongly protects against vaccine serotypes, but the rapid expansion of non-vaccine
serotype disease and the vaccine’s high expense has reduced its overall impact. We have developed Protein Glycan Coupling
Technology (PGCT) as a ﬂexible methodology for making low-cost polysaccharide/protein glycoconjugates recombinantly in
Escherichia coli. We have used PGCT to make a recombinant PCV containing serotype 4 capsular polysaccharide linked to the
Streptococcus pneumoniae proteins NanA, PiuA, and Sp0148. The introduction of the Campylobacter jejuni UDP-glucose 4-epimerase
gene GalE (gne) into E. coli improved the yield of the resulting glycoprotein. PGCT glycoconjugate vaccination generated strong
antibody responses in mice to both the capsule and the carrier protein antigens, with the PiuA/capsule glycoconjugate inducing
similar anti-capsular antibody responses as the commercial PCV Prevnar-13. Antibody responses to PGCT glycoconjugates
opsonised S. pneumoniae and Streptococcus mitis expressing the serotype 4 capsule and promoted neutrophil phagocytosis of S.
pneumoniae to a similar level as antisera generated by vaccination with Prevnar-13. Vaccination with the PGCT glycoconjugates
protected mice against meningitis and septicaemia with the same efﬁcacy as vaccination with Prevnar-13. In addition, vaccination
with the protein antigen components from PGCT glycoconjugates alone provided partial protection against septicaemia and
colonisation. These data demonstrate that a vaccine made by PGCT is as effective as Prevnar-13, identiﬁes PiuA as a carrier protein
for glycoconjugate vaccines, and demonstrates that linking capsular antigen to S. pneumoniae protein antigens has additional
protective beneﬁts that could provide a degree of serotype-independent immunity.
npj Vaccines            (2018) 3:53 ; doi:10.1038/s41541-018-0090-4
INTRODUCTION
Streptococcus pneumoniae (the pneumococcus) is a common
cause of pneumonia, septicaemia, and meningitis, and conse-
quently is responsible for a considerable burden of morbidity and
mortality worldwide.1 S. pneumoniae meningitis is of particular
concern owing to its high case fatality rate and the frequency of
chronic neurological sequelae.2 The pneumococcal conjugate
vaccine (PCV) is highly effective at preventing S. pneumoniae
infections, including meningitis, caused by vaccine serotypes,3–9
but has important drawbacks. First, the dominant disease-causing
serotypes (STs) vary geographically and with age group, yet the
existing PCV formulation is ﬁxed and not readily altered, and
hence has a variable impact among different populations.10
Furthermore, PCV targets only 13 of the 90+ S. pneumoniae
capsular STs, and PCV efﬁcacy has been impaired by the major
expansion of non-vaccine STs.7,9,11–14 Finally, PCV vaccines are
produced by a multi-step chemical conjugation approach that
involves hundreds of quality assurance steps that are expensive,
restricting PCV use in low- and middle-income countries where
the burden of disease is heaviest, and preventing the vaccine from
being cost effective in adults.15,16 Overall, a low-cost S. pneumo-
niae PCV, which is ﬂexible in antigen content to adjust for changes
on S. pneumoniae ecology and provides a degree of ST-
independent protection remains a global imperative.
We have pioneered a low-cost recombinant approach to
making glycoconjugate vaccines termed Protein Glycan Coupling
Technology (PGCT). PGCT uses a C. jejuni oligosaccharyltransferase,
CjPglB, to link protein containing “glycotag” sequences to glycan
structures that are co-expressed in Escherichia coli.17–21 Vaccine
products are puriﬁed by a single step Ni2+ afﬁnity chromato-
graphy procedure from E. coli cells grown in batch culture that can
readily be scaled up for manufacture. Using PGCT to make PCV
would be considerably simpler and have fewer quality control
issues than existing chemical methodologies, resulting in cheaper
vaccine with greater ﬂexibility to alter ST content in response to
the needs of different target populations or geographical
locations, and facilitating rapid reformulation in response to
changes in S. pneumoniae ecology. Another advantage of PGCT is
that different protein antigens can be readily combined with
capsular antigen. To date, only four major carrier proteins have
been licensed for glycoconjugate vaccine formulations; deacti-
vated toxins from Clostridium tetanus and Corynebacterium
diphtheria (CRM197), and two surface expressed proteins from
Haemophilus inﬂuenzae (Protein D) and Neisseria meningitidis.22,23
The efﬁciency of the antibody response to the glycan component
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of a glycoconjugate varies between peptides, yet the efﬁcacy of
multiple carrier proteins has not been tested limiting the
development of glycoconjugate vaccines.24,25 Furthermore, using
protective S. pneumoniae protein antigens as carrier proteins
could provide ST-independent protection via antibody-mediated
opsonophagocytosis,26 inhibition of bacterial protein function,27,28
and Th17 cellular immunity.29–31 Such a vaccine may also have
theoretical advantages in preventing meningitis as antibodies to
selected surface protein antigens could prevent penetration of the
blood–brain barrier.32–34
PCGT has been used to make an effective prototype vaccine
against Francisella tularensis20 and a Shigella ﬂexneri PGCT vaccine
that has completed phase one trials.21 We have shown PGCT can
make recombinant S. pneumoniae capsular polysaccharides from
four STs,35 but whether these capsular products can induce a
similar level of protection as PCV has not been explored. These
data are essential as proof of principle that the PGCT approach is a
viable alternative to conventional manufacture of PCVs. Further-
more, whether S. pneumoniae protein antigens are effective carrier
proteins for capsular antigens while simultaneously stimulating
protective anti-protein immunity has not been investigated. To
assess these gaps, we have tested in murine models the efﬁcacy of
a trivalent PCV made using PGCT to conjugate ST4 capsule to
three S. pneumoniae protein antigens, an N-terminal fragment of
NanA, a multifaceted virulence factor that promoted growth and
survival in the nasopharyngeal tract, brain endothelial cell
invasion, and synergistic infection with Inﬂuenza A,32,36,37 the
Th17-stimulating antigen Sp014827 and the ABC transporter
lipoprotein PiuA.38,39 These antigens have previously been shown
to be effective vaccine antigens in mouse models, and were
chosen to speciﬁcally target prevention of meningitis or
nasopharyngeal colonisation.
RESULTS
The UDP-glucose 4-epimerase GalE improves glycoprotein
production
Using PGCT to produce recombinant glycoconjugates of S.
pneumoniae ST4 capsule material linked to the S. pneumoniae
protein antigens PiuA, Sp0148 and NanA initially resulted in
relatively poor glycoconjugate yields (Fig. 1). We hypothesised
that the intracellular availability of undecaprenyl phosphate carrier
N-acetyl galactosamine (UDP-GalNac), the reducing end sugar
required for ST4 capsule production, may be a limiting factor for
ST4 capsule production by E. coli.35 Hence, a plasmid containing
the gene encoding the C. jejuni UDP-glucose 4-epimerase GalE
Fig. 1 Analysis of recombinant proteins from glycoprotein expression strains. a-c Immunoblot analysis of decreasing concentrations of
recombinant glycoproteins from galE+ and galE- E. coli strains. Fluorescent intensity of the signal from the glycosylated protein bands (green
channel) was measured by densitometry using the LI-COR odyssey ﬂuorescent imaging system and are displayed as mean ± SEM from three
replicate experiments. Red channel: mouse anti-His IgG; Green channel: rabbit anti-Type 4 antiserum. d-h Anti-capsular polysaccharide
antibody levels in antiserum measured from mice (n= 8) vaccinated with recombinant glycoproteins (closed circles) or cognate
unglycosylated antigens (open squares). Antiserum from Prevnar-13 (closed circles) and PBS vaccinated (open squares) animals were included
as controls. Results displayed as mean ± SEM from technical replicates
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(gne), which reversibly converts UDP-GlcNac to UDP-GalNac40 was
transformed into the PGCT E. coli strain. Densitometry of
immunoblots demonstrated a marked increase in glycoconjugate
yields from GalE+ E. coli, conﬁrming that an increase in
intracellular UDP-GalNac availability improved glycoprotein pro-
duction (Figs. 1a-c). The intensity of glycoconjugate bands varied
between the carrier proteins, with a more intense band seen for
the NanA glycoconjugate, suggesting that glycosylation efﬁciency
varies with the protein antigen used in the PGCT process.
Recombinant PGCT glycoconjugates induces strong antibody
responses against both the capsule and carrier protein antigens
Mice were vaccinated with PGCT glycoconjugates NanA(Sp4), PiuA
(Sp4), and Sp0148(Sp4) prepared from GalE+ isolates using a
three-dose schedule, with cognate unglycosylated antigens (both
singly and in combination, labelled Combo), Prevnar-13, and
phosphate buffered saline (PBS)/adjuvant vaccine groups included
as controls. Serum anti-capsule antibodies were above the limit of
detection in all recombinant PGCT glycoconjugate groups, with no
reactivity detected in groups vaccinated with protein alone
(Figs. 1d-h). Anti-capsule antibody levels varied between groups,
but did not correlate with the relative levels of glycoprotein
present. Although the highest level of glycosylation occurred with
the NanA protein (Fig. 1a), PiuA glycoconjugates stimulated the
most robust anti-capsular immune responses (Fig. 1e). Vaccination
with Combo(Sp4), a combination of all three glycoconjugates,
generated a strong anti-capsule response similar to the response
to Prevnar-13. A sandwich enzyme-linked immunosorbent assay
(ELISA) conﬁrmed that all vaccine groups had good antibody
responses to the carrier proteins, with no evidence that
glycosylation impaired protein antigenicity (Figs. 2a-c).
Antibody recognition of S. pneumoniae in sera from mice
vaccinated with recombinant glycoconjugates
Antibody recognition of S. pneumoniae by sera from vaccinated
mice was assessed by whole-cell ELISA using the homologous S.
pneumoniae ST4 strain TIGR4 or the heterologous ST2 strain D39
(Figs. 2d, e). Sera from mice vaccinated with the PGCT
glycoconjugate PiuA(Sp4) or all three PGCT glycoconjugate,
Combo(Sp4), had signiﬁcantly higher anti-TIGR4 titres than mice
vaccinated with Prevnar-13 (Fig. 2d). Although the response in the
Sp0148(Sp4) vaccine group was lower than that generated by
Prevnar-13, the anti-TIGR4 titre in these animals was signiﬁcantly
higher than in the PBS group. Mice vaccinated with the NanA
glycoconjugate generated a nonsigniﬁcant increase in anti-TIGR4
titres compared with PBS vaccinated animals. Signiﬁcant anti-
TIGR4 titres were also recorded following vaccination with
unglycosylated PiuA and the combination of all three unglycosy-
lated proteins, indicating that the anti-protein antibody response
recognised S. pneumoniae. As expected, anti-D39 responses did
not differ between glycoconjugate and protein only vaccine
groups with a signiﬁcant increase in antibody titre to D39 in mice
vaccinated with Sp0148, Sp0148(Sp4), or the combination of all
three proteins alone, and nonsigniﬁcant increases for the
remaining PGCT vaccine groups (Fig. 2e).
Recognition of natural pneumococcal antigens was conﬁrmed
by immunoblotting S. pneumoniae lysates (Fig. 2f). Probing the
TIGR4 lysates with sera from mice vaccinated with PGCT
glycoconjugates resulted in a diffuse high molecular weight
signal that represented capsule material. The immunoblot signal
for capsular material was weaker for TIGR4 lysates probed with
sera from Sp0148(Sp4) and NanA(Sp4) vaccinated mice, compa-
tible with the results of the capsule ELISAs (Figs. 1d-h), and as
expected was absent for the D39 lysates. Bands of the expected
molecular weight for NanA, Sp0148, and PiuA were present when
TIGR4 lysates were probed with the corresponding antisera
(Fig. 2f). Consistent with the results of the whole-cell ELISAs,
probing D39 lysates resulted in a good signal representing Sp0148
(stronger than for the TIGR4 lysates), a weak signal for PiuA, and
no detectable signal representing NanA. Together these data
indicate that vaccination with the PGCT glycoconjugates gener-
ated antibodies to both the ST4 capsule and protein antigens, but
recognition of the latter varied between S. pneumoniae strains.
Antibodies induced by recombinant glycoconjugates opsonised
live S. pneumoniae
Flow cytometry assays were used to assess whether antibody
induced by vaccination with PGCT glycoconjugates can opsonise
live S. pneumoniae. To speciﬁcally investigate anti-capsular
recognition, we assessed IgG binding to a S. mitis mutant
expressing the S. pneumoniae ST4 capsule (S. mitis(SpT4)).41 No
recognition of wild-type S. mitis was detected (Figure S2), but IgG
in sera from mice vaccinated with each of the PGCT glycoconju-
gates or Prevnar-13 bound to S. mitis(SpT4) (Figs. 3a, b). The
degree of IgG binding varied between vaccine groups, with S.
mitis(SpT4) recognition in sera from only four and six mice
vaccinated with Sp0148(Sp4) or NanA(Sp4), respectively, whereas
sera from all eight mice vaccinated with PiuA(Sp4) or Combo(Sp4)
caused signiﬁcant IgG binding to S. mitis(SpT4) at a comparable
level to that seen for the Prevnar-13 vaccinated group (Fig. 3b). No
antibody deposition on the S. mitis(SpT4) strain was seen in sera
from mice vaccinated with unglycosylated protein antigens,
conﬁrming a lack of cross reactivity between the pneumococcal
carrier proteins and the S. mitis cell surface. These data combined
with the data from Figs. 1 and 2 conﬁrm that the PiuA(Sp4)
glycoconjugate induced an anti-capsular antibody response that
was similar in strength to Prevnar-13 and was signiﬁcantly
stronger than the response to the NanA(Sp4) and Sp0148(Sp4)
glycoconjugates.
To assess opsonisation of S. pneumoniae, the ﬂow cytometry
IgG-binding assays were repeated using different S. pneumoniae
strains. Incubation of TIGR4 with descending dilutions of pooled
sera from mice vaccinated with PGCT glycoconjugates demon-
strated dose-dependent IgG binding (Fig. 3c). Comparison of the
geometric mean ﬂuorescence intensity (gMFI) readings with a
standard curve generated using antiserum from Prevnar-13
vaccinated mice revealed high levels of IgG binding to S.
pneumoniae in serum from mice vaccinated with the individual
glycoconjugates and Combo(Sp4) (Fig. 3d). In addition, there were
detectable levels of surface IgG binding in sera from mice
vaccinated with unglycosylated Sp0148 or all three unglycosylated
proteins combined (Fig. 3d), but not for sera obtained from
unglycosylated NanA or PiuA. To assess recognition of the
individual protein antigens, IgG binding to other capsular STs of
S. pneumoniae was assessed and presented as the proportion of
bacteria positive for surface IgG and the intensity of IgG binding
on the positive bacteria (Figs. 4a-d). IgG recognition was generally
weaker than for the TIGR4 strain and varied between strains, with
good levels of IgG binding to the ST23F strain, some binding to
the ST2 strain, but little binding to the ST6B strain. The ability of
each protein antigen to promote IgG binding also varied between
STs; for example, NanA induced the weakest responses against the
ST23F strain, and Sp0148 for the TIGR4 strain. This perhaps reﬂects
differences between strains in the expression level and surface
accessibility of individual protein antigens.
Immunoﬂuorescence of IgG binding to S. pneumoniae in sera from
PGCT glycoconjugate vaccinated mice
Recognition of homologous and heterologous pneumococcal
isolates was further investigated by ﬂuorescence microscopy
(Fig. 4e). Incubation in sera from Prevnar-13 vaccinated mice
caused bright, uniform surface staining for all the vaccine STs
tested (ST4, ST6B, ST19F, and ST23F) but not the non-vaccine
ST2 strain D39. When incubated in sera from mice vaccinated with
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Combo(Sp4), only the TIGR4 strain had a similar level of bright,
uniform staining across the bacterial surface. However, a weaker
and patchy pattern of staining was seen for all STs incubated in
sera from mice vaccinated with either the glycosylated Combo
(Sp4) or unglycosylated Combo of all three protein antigens
(Fig. 4e). Together the ELISA, ﬂow cytometry, and immunoﬂuor-
escence data demonstrate that PGCT glycoconjugates induced
anti-capsular IgG responses that varied in strength between carrier
proteins, but were similar in strength for PiuA glycoconjugates to
those induced by Prevnar-13. In addition, the PGCT
Fig. 2 Vaccination with recombinant glycoproteins generates antibodies that recognise homologous and heterologous pneumococcal
isolates. a-c Anti-carrier protein antibodies were measured from mice vaccinated with Combo(Sp4) (closed circles) or Combo (open squares)
by sandwich ELISA using a monoclonal anti-His capture antibody and recombinant, unglycosylated carrier proteins. Data are displayed as
mean ± SEM from technical replicates. d, e Anti-ST4 d and anti-ST2 e antibodies were measured by whole-cell ELISA using pooled antiserum
from the glycosylated (black bars) and unglycosylated (white bars) vaccine groups. Data are displayed as mean ± SEM from three separate
cultures. *p < 0.05 vs PBS, #p < 0.05 protein vs glycoprotein, †p < 0.05 vs Prevnar-13 one-way ANOVA with Bonferroni’s post-test. f Immunoblot
analysis of concentrated lysate from ST4 and ST2 overnight cultures using pooled antiserum from the glycosylated and unglycosylated
vaccine groups. Molecular mass markers are given in kilodaltons
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glycoconjugates stimulated antibody responses to protein anti-
gens that partially opsonised heterologous S. pneumoniae STs
(Fig. 4) and therefore potentially provide some degree of ST-
independent protection.
Ability of sera from mice vaccinated with recombinant PGCT
glycoconjugates to support neutrophil phagocytosis
To determine if antibody responses to PGCT glycoconjugates can
promote opsonophagocytosis, neutrophil uptake assays were
performed.42 Incubation in sera from mice vaccinated with the
PiuA(Sp4) glycoconjugate or Combo(Sp4) promoted neutrophil
uptake of the TIGR4 S. pneumoniae strain (Fig. 5a). In contrast, sera
from mice vaccinated with the Sp0148(Sp4), NanA(Sp4), or the
unglycosylated antigens (individually and in combination) failed
to promote neutrophil phagocytosis in this assay (Fig. 5b), and
none of the sera from any of the PGCT glycoconjugate vaccine
groups promoted neutrophil uptake of three heterologous STs
(ST2, ST23F, and ST19F) (Figs. 5b-e). These data conﬁrm that
recombinant PGCT type 4 capsular antigen can induce functionally
important IgG, but the relatively patchy and low level of IgG
binding to the protein antigens alone was not sufﬁcient to
promote neutrophil phagocytosis in the conditions used for this
assay.
Protective efﬁcacy of vaccination of mice with recombinant
glycoconjugates produced by PGCT
Mouse models of colonisation, pneumonia with sepsis, and
meningitis were used to assess the protective efﬁcacy of
vaccination with Combo(Sp4) or Combo, using Prevnar-13 as a
positive control. In the model of TIGR4 colonisation, mice
vaccinated with the Combo had reduced TIGR4 colony forming
units (CFU) in nasal washes recovered seven days after initial
colonisation (Fig. 6a). In the Prevnar-13 and Combo(Sp4) vaccine
groups, there was an approximately 1-log10 reduction in nasal
wash CFU compared with the control group, but these differences
were not statistically signiﬁcant. In the TIGR4 pneumonia with
septicaemia model, vaccination with the Combo(Sp4) almost
completely prevented septicaemia and resulted in an approxi-
mately 1-log10 reduction in lung CFU, a similar level of protection
to that provided by Prevnar-13 (Fig. 6b). Although not statistically
signiﬁcant, there was also a reduction in median CFU/ml
recovered from the blood in mice vaccinated with the combina-
tion of the unglycosylated proteins. In the meningitis model, mice
were given an intranasal inoculation of WCH43, a ST4 isolate
known to cause meningitis in a murine model.34 In this model,
vaccination with Combo(Sp4) again resulted in a similar level of
protection to that provided by vaccination with Prevnar-13, with
complete prevention of septicaemia and meningitis and an
approximately 3-log10 reduction in lung CFU (Fig. 6c). For mice
Fig. 3 Flow cytometry analysis of antibody deposition on streptococcal species. a Representative histograms for antibody deposition on S.
mitis(SpT4) in 10% antiserum from glycosylated (red shading) and unglycosylated (grey shading) vaccine groups. PBS vaccinated serum
(dashed line) was included as a control. b Antibody deposition measured using a ﬂow cytometry assay on S. mitis(SpT4) in 10% murine
antiserum (n= 8) from glycosylated (closed circles) and unglycosylated (open squares) vaccine groups. Red dots indicate reactions containing
reduced antiserum concentrations (5 vs 10%) in high titre samples. *p < 0.05 Kruskal–Wallis with Dunn’s post-test (vs PBS). c Examples of ﬂow
cytometry histograms for antibody deposition on the TIGR4 S. pneumoniae strain in 2% (red shading), 0.2% (grey shading), and 0.02% (dashed
line) antiserum from glycosylated vaccine groups. d Antibody deposition on TIGR4 in pooled antiserum from mice vaccinated with
glycosylated or unglycosylated vaccines. Deposition titres were determined using bacteria incubated with decreasing concentrations of
Prevnar-13 antiserum to generate a standard curve. Results displayed as mean ± SEM from technical replicates
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Fig. 4 Antibody deposition on non-serotype 4 pneumococci. a-d Representative histograms and antibody deposition on homologous and
heterologous pneumococcal isolates in 1% pooled antiserum from mice vaccinated with glycosylated NanA (grey shading), Sp0148 (red
shading), or PiuA (blue shading) or normal mouse serum (dashed line). Black bars represent the percentage of PE+ bacteria and grey bars
represent the gMFI of the positive population. Gates were set such that 5–10% of events were PE+ in the normal mouse serum (NMS)
reactions to account for strain speciﬁc differences in auto ﬂuorescence. Data are displayed as mean ± SEM from technical replicates. e
Immunoﬂuorescent staining of homologous and heterologous pneumococcal isolates using antiserum from mice vaccinated with the
combination vaccine (green channel) and pneumococcal Omni serum (red channel). Length of scale bar is equal to 5 µm
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vaccinated with Combo (proteins alone), median blood, lung, and
brain CFU were all lower than results for the negative control
although only the blood data were statistically signiﬁcant (Fig. 6c).
Overall, these data demonstrate that the PGCT glycoconjugate
vaccine was protective against infection with the homologous S.
pneumoniae ST, providing a level of protection as good as
vaccination with Prevnar-13. Furthermore, the S. pneumoniae
protein components generated some protective responses
independent of capsular antigen, suggesting that they may
provide a degree of ST-independent protection.
DISCUSSION
Despite the efﬁcacy of the PCV, S. pneumoniae remains a major
pathogen driving worldwide infectious mortality and morbidity.
Extension of routine vaccination with PCV to all countries will be
necessary to reduce this substantial disease burden, but this is
prevented by the current high cost of chemically coupled
preparation of PCVs. Furthermore, routine use of PCV drives ST
replacement leading to a probable reduction in vaccine efﬁcacy
over time. Thus, there is an urgent need to reduce PCV production
costs, increase the ﬂexibility of PCV manufacture to allow
additional STs to be introduced in response to changes in S.
pneumoniae epidemiology, and preferably improve the vaccine to
include additional non-ST-dependent immunity. In this report, we
demonstrate recombinant S. pneumoniae glycoconjugates
expressed in E. coli cells using PGCT can fulﬁl these requirements,
making PGCT a viable alternative methodology for the
manufacture of a new generation of PCVs. Our major ﬁndings
are: (a) S. pneumoniae capsular material made in E. coli and linked
to a carrier protein using PGCT stimulates anti-capsular antibodies;
(b) anti-capsular immunogenicity of PGCT glycoconjugates varies
between carrier proteins, with at least one S. pneumoniae protein
antigen (PiuA) stimulating anti-capsular antibody levels similar to
those induced by a commercial PCV; (c) the carrier proteins are
also immunogenic, stimulating antibody responses able to offer
some degree of protection against colonisation, meningitis, and
sepsis independent of capsular antibody; and (d) that in mouse
models of colonisation, pneumonia, and meningitis vaccination
with our PGCT glycoconjugate provides a similar level of
protection as Prevnar-13. An additional ﬁnding is that glycocon-
jugate yield and PGCT efﬁciency can be improved by expressing a
UDP-glucose 4-epimerase, GalE, in the E. coli host strain.
Our data have been obtained using a single capsular ST, but to
be a viable methodology for manufacturing PCV the number of
STs will have to be expanded to match the up to 13 STs included
in existing PCVs. Several other S. pneumoniae capsule STs have
been expressed in E. coli and coupled to a variety of carrier
proteins using the C. jejuni (Wren, unpublished data). However, the
C. jejuni PglB can only transfer polysaccharides ending in an
acetylated sugar,43 and thus is suitable for only 12 STs (1, 4, 5, 12F,
12A, 12B, 25F, 25A, 38, 44, 45, and 46). To overcome this problem,
additional bacterial oligosaccharyltransferases with different sugar
speciﬁcities,44,45 or with more promiscuous recognition of
glycans46 are being actively developed for PGCT to allow
production of glycoconjugates that include the majority of vaccine
Fig. 5 Effect of antiserum samples on interaction of S. pneumoniae with human neutrophils. a Examples of ﬂow cytometry histograms for fresh
human neutrophils incubated with FAM-SE labelled TIGR4 when opsonised in 20% antiserum from glycosylated (red shading) or
unglycosylated (grey shading) vaccine groups and 5% baby rabbit complement. PBS vaccinated serum (dashed line) was included as a control.
b Percent association of fresh human neutrophils with TIGR4 when opsonised in 20% antiserum (n= 8) from glycosylated (closed circles) or
unglycosylated (open squares) vaccine groups and 5% baby rabbit complement. Antiserum from Prevnar-13 (closed circles) and PBS
vaccinated (open squares) animals were included as controls. *p < 0.05 Kruskal–Wallis with Dunn’s post-test (vs PBS). c-e Percent association of
fresh human neutrophils with non-type 4 pneumococci when opsonised in 20% antiserum (n= 6) from glycosylated (closed circles) or
unglycosylated (open squares) vaccine groups and 5% baby rabbit complement. Antiserum from Prevnar-13 (closed circles) and PBS
vaccinated (open squares) animals were included as controls
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STs, as well as vaccine-replacement STs. Creating a range of E. coli
cells expressing different S. pneumoniae STs will allow the ST
content of a PGCT PCV to be altered rapidly in response to
changes in ST prevalence or tailored to speciﬁc target populations,
a major additional advantage over PCVs made using conventional
chemical conjugation methodologies.
The presented data demonstrate that glycoconjugates pro-
duced by PGCT are capable of inducing an equivalent anti-
capsular antibody response to Prevnar-13 that is highly protective
in the pneumonia model, causing almost complete prevention of
septicaemia. As a consequence, any additional beneﬁt against ST4
S. pneumoniae strains of the anti-protein response to vaccination
with PGCT PCV would be hard to detect, and require mouse group
sizes that are ethically unjustiﬁed. Instead, the main clinical beneﬁt
of anti-protein responses will be in extending protection to
heterologous STs. In addition, making PCVs using PGCT rather
than by chemical reaction still has considerable practical
advantages in reducing cost and complexity of the manufacturing
process. Although our results for protection against colonisation
showed the PGCT PCV reduced nasopharyngeal CFU at 7 days
these data did not reach statistical signiﬁcance. The results for the
PGCT PCV were similar to those for Prevnar-13, which despite the
known effects of Prevnar-13 in preventing colonisation in humans
also did not show statistical signiﬁcant reductions in CFU
compared with the controls. Additional experiments with an
earlier or later timepoint or a larger n number are necessary to
fully deﬁne the effects of the PGCT PCV on nasopharyngeal
carriage.
A potential important advantage of using S. pneumoniae protein
antigens as carrier proteins for a PCV made using PGCT is the
induction of protective ST-independent anti-protein immunity
that could include both humoral immunity and Th17 responses,
which are thought to enhance mucosal immunity compared with
antibody responses alone.27,47,48 We have investigated this using
three conserved S. pneumoniae protein antigens known to be
protective in vivo;27,49 NanA, chosen as it is required for S.
pneumoniae to cross the blood–brain barrier and hence anti-NanA
could speciﬁcally prevent meningitis;32 Sp0148, chosen as it is a
recognised Th17 antigen that promotes mucosal immunity;27 and
PiuA, chosen as it is highly expressed by S. pneumoniae colonising
the nasopharynx so could improve prevention of colonisation.39
Our data conﬁrmed that vaccination with PGCT glycoconjugates
containing NanA, PiuA, and Sp0148 carrier proteins generated
strong anti-protein antibody responses. However, as previously
recognised with other protein antigens, these anti-protein anti-
body responses had weaker opsonising potential than anti-
capsular antibody, and was unable to support in vitro neutrophil
phagocytosis under the test conditions we used. This probably
reﬂects the lower quantities of expression of surface proteins
compared with capsular antigen and their protection from
antibody recognition by the capsule.50 Furthermore, using ﬂow
cytometry and immunoﬂuorescence we have shown that despite
Fig. 6 Vaccination with recombinant glycoconjugates provides protection against several pneumococcal disease aetiologies. Mice were
vaccinated with Combo(Sp4), Combo, Prevnar-13, or PBS+ adjuvant as outlined in the methods. a Mice challenged intranasally with 1 × 107
CFU of TIGR4 were culled seven days post-infection and bacterial loads were assessed by nasal washing. b, c Mice were infected intranasally
with 1 × 107 CFU of TIGR4 b or 2 × 106 CFU of WCH43 c and culled after 24 or 48 h respectively. Bacterial burdens in the blood and organ
homogenates were determined by serial dilution and plating. *p < 0.05 Kruskal–Wallis with Dunn’s post-test (vs PBS)
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high levels of conservation (at least for Sp0148 and PiuA), the
strength of antibody recognition of each S. pneumoniae protein
antigen differs between S. pneumoniae strains. This probably
reﬂects differences in levels of protein expression between strains,
and also differences between capsular STs in allowing antibody
access to subcapsular protein antigens.51 Repeat IgG opsonisation
experiments with antisera to individual carrier proteins could help
identify which protein dominates the response to different
heterologous strains. Antiserum raised against Sp0148 was shown
to cross react with TIGR4 and D39 by whole-cell ELISA, conﬁrming
that this antigen is expressed at high enough levels to promote
recognition in some settings. The ability of Sp0148 to generate
cross reactive antiserum is supported by data from a recent global
study predicting that inclusion of the TIGR4 variant of Sp0148 in a
multivalent protein vaccine would potentially provide 98% cover-
age against ST1 pneumococcus worldwide.52 Interestingly, anti-
protein immunity alone did cause a statistically signiﬁcant
reduction in nasopharyngeal colonisation, which could suggest
these antigens can induce a Th17 response similar to that
described previously for Sp0148.27
However, protein antigen selection will need to take into
account not only their degree of conservation between strains but
also variation in expression levels and accessibility to antibody,
factors that cannot easily be predicted using bioinformatics.
Indeed, recognition of the selected proteinaceous virulence
factors may vary drastically in vivo where capsule and virulence
protein expression may be modulated in response to a variety of
external stimuli. Although it is likely that increased capsule
expression will make recognition of subcapsular antigens in the
blood more difﬁcult, the effects in the nasopharynx and
blood–brain interface are harder to predict.
Despite the limited effects of antibody targeting NanA, Sp0148,
and PiuA in supporting neutrophil phagocytosis, vaccination with
these proteins alone reduced bacterial CFU present in blood and
meninges after challenge with S. pneumoniae. These data
demonstrate the protective potential of including S. pneumoniae
carrier proteins in PGCT glycoconjugates, although the weaker
protective effects of anti-protein compared with anti-capsular
antibody demonstrate a need to identify additional S. pneumoniae
proteins able to induce stronger cross-protective immunity
against multiple S. pneumoniae strains.
The ELISA, ﬂow cytometry, and ﬂuorescence microscopy data all
demonstrate that PiuA is a highly effective carrier protein option
for S. pneumoniae glycoconjugate vaccines, and therefore possibly
for other non-pneumococcal glycoconjugates. This is a major
ﬁnding that has wider implications for vaccine development as
these results suggest PiuA could be an additional carrier protein
for glycoconjugate vaccines to add to the four existing proteins.
Sp0148 and NanA were considerably less effective at generating
anti-capsular antibody responses than PiuA, and it probably most
of the anti-capsule to the Combo(Sp4) vaccine resulted from the
glycosylated PiuA component. The reasons why there were such
marked differences in the efﬁcacy of the carrier protein in
promoting anti-capsular antibody is not clear. Immunoblots
suggested that this is not simply due to a greater quantity of
PiuA glycoconjugate, as the NanA glycoconjugate seemed to be
the most abundant (Fig. 1). Recent data suggest glycoconjugates
generate an antibody response to glycan by presentation of a
glycosylated protein epitope bound to MHCII directly to the T-cell
receptor.24,25 As some protein epitopes will be presented more
efﬁciently, this mechanism would be affected by the protein
carrier and perhaps by the site of covalent linkage to capsular
antigen and therefore explain our data. Screening multiple
additional S. pneumoniae proteins should identify additional
suitable carrier proteins for glycoconjugate vaccines.
In summary, the data presented here demonstrate that a
recombinant S. pneumoniae protein/capsular antigen glycoconju-
gate made by PGCT has a similar efﬁcacy to a commercial PCV in
preventing ST4 infection, but can also induce a degree of anti-
protein protective immunity. With further development to expand
the STs compatible with PGCT and to identify the most effective
cross-protective S. pneumoniae carrier protein antigens, PCVs
made using PGCT could provide a low-cost ﬂexible method of
manufacture that will make PCVs affordable to low- and middle-
income countries.
MATERIALS AND METHODS
Bacterial strains and growth conditions
The bacterial strains used in this study are listed in Table S1. E. coli isolates
were cultured in modiﬁed super optimal broth (SOB)35 or agar at 28 °C,
supplemented with 100 µg/ml ampicillin, 20 µg/ml tetracycline, and/or
80 µg/ml spectinomycin when appropriate. S. pneumoniae were cultured
on Columbia horse blood agar plates (E&O laboratories) or in brain heart
infusion broth at 37 °C+ 5% CO2, supplemented with 5 µg/ml gentamycin
or 75 µg/ml streptomycin when appropriate. S. mitis was cultured in
Todd–Hewitt broth supplemented with 0.5% yeast extract at 37 °C+ 5%
CO2. S. pneumoniae and S. mitis were cultured to an OD600 of
approximately 0.4–0.8 and stored in single use 1 ml aliquots at −80 °C in
20% glycerol.
Synthesis and genetic modiﬁcation of carrier protein genes
DNA sequences, codon optimised for expression in E. coli, encoding
neuraminidase A (NanA, Spd1504) and the ABC transporter proteins PiuA
(Sp1872) and Sp0148 were synthesised commercially in pUC57 and sub-
cloned into pEXT21 as outlined in the supplementary methods (Table S2).
Owing to the large size of full-length NanA, which reduced recombinant
protein yields, the N-terminal lectin-like domain of the protein (essential
for protein function32) was sub-cloned as outlined in the supplementary
methods. Gene sequences for PiuA and Sp0148 were derived from the
genome of the TIGR4 strain, whereas the gene sequence for NanA was
derived from the genome of the D39 strain.
Preparation of expression strains
E. coli W3110 and W311B pB4-4 cell cultures were inoculated 1:100 from
overnights and grown to an OD600 of 0.3–0.6, chilled on ice, pelleted at
4000 × g for 10 min and washed sequentially with 0.5 volumes and then
0.25 volumes of ice cold 10% glycerol. Competent cells were resuspended
in 1/250th volume ice cold 10% glycerol and 50 µl aliquots were
transformed with pEXT21(nanA), pEXT21(piuA), or pEXT21(sp0148) in a
0.2 cm gap cuvette at 2.5 kV, 200Ω, and 25 µF. The C. jejuni UDP-glucose 4-
epimerase GalE (gne) was ampliﬁed from pEXT21(gne) using the pEXT-F/
pEXT-R primer pair and sub-cloned into pEXT20 using the restriction
enzymes EcoRI and PstI (New England Biolabs), before transformation into
W311B pB4-4 pEXT21(nanA/piuA/sp0148) by electroporation as outlined
above. Isolates were stored at −80 °C in 20% glycerol.
Recombinant protein preparation
W3110 pEXT21(nanA/piuA/sp0148) and W311B pB4-4 pEXT20(galE) pEXT21
(nanA/piuA/sp0148) isolates were cultured overnight at 28 °C and sub
cultured 1:100 into SOB for 2–3 h prior to overnight induction with 1mM
isopropyl β-D-1-thiogalactopyranoside (IPTG) and 4mM MnCl2 at 28 °C.
The cells were pelleted at 14,000 × g and lysed using a pressure cell
homogeniser (Stanstead). Lysates were treated with 25 U/ml Benzonase
Nuclease (Sigma-Aldrich) for 20min at RT and 0.2 µm ﬁltered using Millex-
GP Syringe Filters (Millipore). In initial studies, recombinant (glyco)proteins
were puriﬁed using the Ni-NTA puriﬁcation system (Thermo Fisher
Scientiﬁc). For vaccination studies, recombinant (glyco)proteins were
isolated using GE Healthcare His-trap FF columns and an AKTA puriﬁer
with a linear imidazole gradient of 25–250mM. Sample purity was
conﬁrmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) (Figure S1).
SDS-PAGE and immunoblotting
SDS-PAGE and protein transfer was performed using NuPAGE Bis-Tris
protein gels and the iBlot2 transfer system according to the manufacturer’s
instructions (Thermo Fisher). Immunoblotting was performed under
standard conditions using ST4 rabbit anti-capsule antibody (1:1000,
Statens Serum Institut, Denmark), monoclonal mouse anti-His IgG
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(1:5000, Abcam), and detection with 1:10,000 dilutions of goat anti-rabbit
IgG (IRDye800) and goat anti-mouse IgG (IRDye680) and the LI-COR
odyssey ﬂuorescent imaging system and densitometry (LI-COR Biosciences
UK Ltd). TIGR4 and D39 lysates were prepared by pressure lysis of
overnight cultures, 0.2 µm ﬁltered and concentrated using Vivaspin 20
Centrifugal Concentrators (10,000 MWCO). In all, 10 µl aliquots of
concentrated lysate were analysed by immunoblotting using a 1:1000
dilution of murine antiserum and a 1:10,000 dilution of goat anti-mouse
IgG (IRDye800). All blots derived from the same experiment were
processed in parallel.
Vaccination studies
For antiserum generation and pneumonia/meningitis challenge studies,
female 5- to 6-week CD1 mice (Charles River) were vaccinated on day 0
intraperitoneally with recombinant (glyco)proteins singly (10 µg/mouse/
injection) or in combination (Combo/Combo(Sp4), 4 µg each protein/
mouse/vaccination) emulsiﬁed 1:1 in Sigma adjuvant (Sigma-Aldrich), 20 µl
of Prevnar-13 (Wyeth) diluted 1:5 PBS, or PBS and Sigma adjuvant alone.
Booster immunisations were given subcutaneously on days 21 and 35. In
pneumonia and meningitis infection experiments, mice were infected
intranasally with 1 × 107 CFU of TIGR4 or 2 × 106 CFU of WCH43 in 50 µl PBS
under deep isoﬂurane anaesthesia and culled after 24 or 48 h, respectively.
Colonisation studies were performed using mice vaccinated intraperito-
neally as outlined above and boosted intranasally under light isoﬂurane
anaesthesia with 2 µg of the combination vaccines, 20 µl of diluted
Prevnar-13 or PBS. Mice were infected intranasally with 1 × 107 CFU of
TIGR4 in 20 µl PBS under light isoﬂurane anaesthesia, culled 7 days post-
infection, and degree of colonisation assessed by plating serial dilutions of
nasal washes.53 Samples sizes were selected based on previous studies.38,53
No randomisation or blinding was performed. All animal procedures were
approved by the local ethical review process and conducted in accordance
with the relevant, UK Home Ofﬁce approved, project license (PPL70/6510).
Anti-capsule and anti-protein ELISAs
Anti-capsular responses were measured using Nunc Maxisorp plates were
coated with 0.5 µg/well puriﬁed type 4 pneumococcal polysaccharide
(Statens Serum Institut, Denmark) in PBS overnight at 4 °C, using the
indicated dilutions of murine antiserum and a 1:20,000 dilution of
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Abcam).
Anti-capsule titres were determined by comparison with a standard curve
generated using anti-Prevnar antiserum with an arbitrary titre of 1:10,000.
Anti-protein responses were measured by sandwich ELISA using plates
coated with 0.1 µg of monoclonal rabbit anti-His IgG (Abcam) and 1 µg/
well of recombinant protein. For whole-cell ELISAs, TIGR4 and D39 cultures
were grown to an OD600 of approximately 0.4–0.8, washed and
resuspended to an OD600 of 0.4 in 10% glycerol, and plates incubated
with 100 µl/well for 2 h at RT before ﬁxation in 4% formaldehyde for
20min. Plates were washed and incubated with a 1:1000 dilution of murine
antiserum for 2 h at 28 °C using HRP-conjugated goat anti-mouse IgG for
detection as outlined above.53
Flow cytometry assays
Antibody deposition and neutrophil uptake assays were performed as
previously described.53 Brieﬂy, IgG binding was assessed using 2 × 106 CFU
bacteria in a ﬁnal volume of 50 µl, detection with a 1:100 dilution of
phycoerythrin (PE)-conjugated goat anti-mouse IgG (Thermo Fisher), and
measurement of ﬂuorescence intensity using a FACSVerse (BD Bioscience).
TIGR4 deposition titres were determined by comparison with a standard
curve, generated using anti-Prevnar antiserum with an arbitrary titre of
1:10,000. Neutrophils were puriﬁed from healthy human donors using the
MACSxpress magnetic puriﬁcation system according to the manufacturer’s
instructions (Miltenyi Biotechnology), and 2 × 104 neutrophils incubated for
30min in a ﬁnal volume of 50 µl per sample with 2 × 106 FAM-SE labelled S.
pneumoniae that had been pre-opsonised with diluted murine antiserum
for 30min at 37 °C. The reactions were ﬁxed with 100 µl/well 4%
paraformaldehyde and the ﬂuorescence intensity of the neutrophil
population was measured using the FACSVerse system. Experiments using
human cells were approved by the joint University College London/
University College Hospitals National Health Service Trust Human Research
Ethics Committee, and informed consent was obtained from all
participants.
Fluorescence microscopy
Fluorescent microscopy was performed using formaldehyde ﬁxed bacteria
incubated with a 1:200 dilution of mouse antiserum and a 1:500 dilution of
pneumococcal Omni serum (Statens Serum Institut) for 30 min at RT. PBS
washed slides were incubated with a 1:10,000 dilution of Alexaﬂuor488-
conjugated anti-mouse IgG and Alexaﬂuor568-conjugated anti-rabbit IgG
for 15min, incubated with a 1:10,000 dilution of 4',6-diamidino-2-
phenylindole (DAPI) in PBS and mounted in DAKO mounting medium
(Agilent). Fluorescent images were produced using an Olympus TIRF
confocal microscope and Fluoview software (Olympus Lifesciences).
Statistical analysis
Statistical analyses were performed using GraphPad Prism. ELISA data were
analysed using one-way analysis of variance (ANOVA) with Bonferroni’s
correction. Opsonisation, phagocytosis, and vaccine experiments were
analysed using a Kruskal–Wallis with Dunn’s post-test. Flow cytometry data
analysis was performed using FlowJo software.
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